Premium
Why isn't the NHS making the most of biosimilar insulin?
Author(s) -
Greener Mark
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1781
Subject(s) - biosimilar , medicine , diabetes mellitus , insulin , intensive care medicine , endocrinology
With cheaper biosimilar insulins now reaching the UK market, there are opportunities for potential cost savings in diabetes management. However, uptake in the NHS has so far been low. In this article, Mark Greener explores the possible reasons for this.